{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:30:13Z","timestamp":1784946613237,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1917-8","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T14:03:09Z","timestamp":1559829789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9\u00a0years of experience from the Rhumadata\u00ae clinical database and registry"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6585-7695","authenticated-orcid":false,"given":"Denis","family":"Choquette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evo","family":"Alemao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelien","family":"Postema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Raynauld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Coupal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"issue":"8","key":"1917_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.110207","volume":"39","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association Recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559\u201382.","journal-title":"J Rheumatol"},{"issue":"6","key":"1917_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"1917_CR3","unstructured":"R\u00e9gie de l\u2019assurance maladie Qu\u00e9bec. Liste des m\u00e9dicaments \u2013 \u00c9tablissements: D\u00e9p\u00f4t l\u00e9gal \u2014 Biblioth\u00e8que et Archives nationales du Qu\u00e9bec; 2018 [updated 24 mai 2018. Available from: http:\/\/www.ramq.gouv.qc.ca\/SiteCollectionDocuments\/liste_med\/2019\/liste_med_2019_05_23_fr.pdf . Accessed 14 Aug 2018."},{"issue":"4","key":"1917_CR4","first-page":"660","volume":"35","author":"V Codullo","year":"2017","unstructured":"Codullo V, Iannone F, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, et al. Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clin Exp Rheumatol. 2017;35(4):660\u20135.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"1917_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172\u201380.","journal-title":"JAMA."},{"key":"1917_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12891-015-0636-9","volume":"16","author":"HG N\u00fc\u00dflein","year":"2015","unstructured":"N\u00fc\u00dflein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, et al. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord. 2015;16:176.","journal-title":"BMC Musculoskelet Disord"},{"issue":"Suppl 3","key":"1917_CR7","first-page":"574","volume":"68","author":"M Schiff","year":"2009","unstructured":"Schiff M, Le Bars M, Gaillez C, Wu G, Poncet C, Genovese M. Efficacy and safety of abatacept in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy by number of prior anti-TNF therapies used. Ann Rheum Dis. 2009;68(Suppl 3):574 SAT0102.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1917_CR8","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1136\/annrheumdis-2014-205325","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis. 2014;73(12):2174\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9685","key":"1917_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210\u201321.","journal-title":"Lancet."},{"issue":"2","key":"1917_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","volume":"47","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Giulio Favalli E, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017;47(2):183\u201392.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"1917_CR11","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s12325-017-0617-5","volume":"34","author":"B Chastek","year":"2017","unstructured":"Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W. Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. Adv Ther. 2017;34(11):2422\u201335.","journal-title":"Adv Ther"},{"issue":"6","key":"1917_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015;74(6):979\u201384.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1917_CR13","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53(9):1664\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1917_CR14","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s12325-017-0578-8","volume":"34","author":"W Wei","year":"2017","unstructured":"Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, et al. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017;34(8):1936\u201352.","journal-title":"Adv Ther"},{"key":"1917_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/CEOR.S115706","volume":"8","author":"MM Bonafede","year":"2016","unstructured":"Bonafede MM, Curtis JR, McMorrow D, Mahajan P, Chen CI. Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. Clinicoecon Outcomes Res. 2016;8:707\u201315.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"1917_CR16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1681\/ASN.V132559","volume":"13","author":"A Yamada","year":"2002","unstructured":"Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002;13(2):559\u201375.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1917_CR17","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/rmdopen-2017-000538","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nusslein HG, et al. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open. 2017;3(2):e000538.","journal-title":"RMD Open"},{"issue":"1","key":"1917_CR18","doi-asserted-by":"publisher","first-page":"e000345","DOI":"10.1136\/rmdopen-2016-000345","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten R, Nusslein HG, Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive: 6-month results from a real-world, international, prospective study. RMD Open. 2017;3(1):e000345.","journal-title":"RMD Open."},{"issue":"1","key":"1917_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-016-1179-7","volume":"18","author":"LR Harrold","year":"2016","unstructured":"Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, et al. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther. 2016;18(1):280.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1917_CR20","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/1756-185X.13243","volume":"21","author":"Graeme Jones","year":"2017","unstructured":"Jones G, Hall S, Bird P, Littlejohn G, Tymms K, Youssef P, et al. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Int J Rheum Dis. 2018;21(8):1581\u201390.","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"5","key":"1917_CR21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","volume":"55","author":"C Lahaye","year":"2016","unstructured":"Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology\u2019s ORA registry. Rheumatology (Oxford). 2016;55(5):874\u201382.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1917_CR22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096\u2013103.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1917_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1917_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28\u201338.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1917_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nrrheum.2017.81","volume":"13","author":"E Nikiphorou","year":"2017","unstructured":"Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017;13(8):503\u201310.","journal-title":"Nat Rev Rheumatol"},{"issue":"5 Suppl 39","key":"1917_CR26","first-page":"S195","volume":"23","author":"RF van Vollenhoven","year":"2005","unstructured":"van Vollenhoven RF, Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S195\u2013200.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1917_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3899\/jrheum.141288","volume":"42","author":"N Takahashi","year":"2015","unstructured":"Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, et al. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks. J Rheumatol. 2015;42(5):786\u201393.","journal-title":"J Rheumatol"},{"issue":"8","key":"1917_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2217\/cer-2017-0010","volume":"6","author":"A Nadkarni","year":"2017","unstructured":"Nadkarni A, McMorrow D, Fowler R, Smith D. Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics. J Comp Eff Res. 2017;6(8):659\u201369.","journal-title":"J Comp Eff Res"},{"issue":"5","key":"1917_CR29","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s12272-014-0337-1","volume":"37","author":"HL Kim","year":"2014","unstructured":"Kim HL, Lee MY, Park SY, Park SK, Byun JH, Kwon S, et al. Comparative effectiveness of cycling of tumor necrosis factor-alpha (TNF-alpha) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-alpha inhibitor using a Bayesian approach. Arch Pharm Res. 2014;37(5):662\u201370.","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1917_CR30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.clinthera.2016.03.013","volume":"38","author":"KA Betts","year":"2016","unstructured":"Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ. Economic burden and treatment patterns of cycling between conventional synthetic disease-modifying antirheumatic drugs among biologic-treated patients with rheumatoid arthritis. Clin Ther. 2016;38(5):1205\u201316.","journal-title":"Clin Ther"},{"issue":"9","key":"1917_CR31","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","volume":"77","author":"Kim Lauper","year":"2018","unstructured":"Lauper K, Nordstrom DC, Pavelka K, Hernandez MV, Kvien TK, Kristianslund EK, et al. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis. 2018;77(9):1276\u201382.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"1917_CR32","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10067-015-3066-z","volume":"34","author":"Z Rotar","year":"2015","unstructured":"Rotar Z, Hocevar A, Rebolj KA, Praprotnik S, Tomsic M. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. Clin Rheumatol. 2015;34(10):1787\u201393.","journal-title":"Clin Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1917-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1917-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1917-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T18:20:01Z","timestamp":1663611601000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1917-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1917"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1917-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"8 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rhumadata\u00ae is approved on an annual basis by an ethics committee (Institutional Review Board Services, Aurora, Ontario, Canada). All registry subjects were required to provide written informed consent prior to participating.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DC is a consultant and speaker for Amgen, AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Merck, Novartis, Pfizer, Roche, and Sandoz. LB is a consultant and speaker for, and has received research support from, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Roche, and UCB; in addition, LB has received speaker fees from Merck and research support from Merck and Sanofi. EA and RP are employees of and\/or shareholders of and\/or hold stock options in Bristol-Myers Squibb. BH is a consultant for AbbVie, Amgen, Lilly, Merck, Pfizer, and UCB; in addition, BH is a speaker for Pfizer and has received research support from AbbVie. J-PR is a speaker and consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB; in addition, J-PR has received consulting fees and research support from Arthrovision Inc. LC declares no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}